The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugsMourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatryAmphetamine, past and present--a pharmacological and clinical perspectiveNeural correlates of the LSD experience revealed by multimodal neuroimagingTranslocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular functionAssociation of the anxiogenic and alerting effects of caffeine with ADORA2A and ADORA1 polymorphisms and habitual level of caffeine consumptionNeural correlates of the psychedelic state as determined by fMRI studies with psilocybinPsilocybin with psychological support for treatment-resistant depression: an open-label feasibility studyBehavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and meta-analysis.Estimating the harms of nicotine-containing products using the MCDA approachWCA recommendations for the long-term treatment of generalized anxiety disorderResolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitorsThe other face of depression, reduced positive affect: the role of catecholamines in causation and cureIn vivo imaging of microglial activation by positron emission tomography with [(11)C]PBR28 in the 5XFAD model of Alzheimer's diseaseSerotonin 5-HT1A receptor binding in people with panic disorder: positron emission tomography studyDevelopment of a rational scale to assess the harm of drugs of potential misuseAlcohol alternatives--a goal for psychopharmacology?Doing it by numbers: a simple approach to reducing the harms of alcoholPersonalized risk assessment of drug-related harm is associated with health outcomesLSD modulates music-induced imagery via changes in parahippocampal connectivity.Structural and functional brain changes in posttraumatic stress disorder.Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety.Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.Determination of [(11)C]PBR28 binding potential in vivo: a first human TSPO blocking study.Drug harms in the UK: a multicriteria decision analysis.Generic legislation of new psychoactive drugs.Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis.Tolerability and safety aspects of mirtazapine.5-HT radioligands for human brain imaging with PET and SPECTHighlights of the international consensus statement on major depressive disorder.Endogenous opioid release in the human brain reward system induced by acute amphetamine administration.Alcohol and Relatively Pure Cannabis Use, but Not Schizotypy, are Associated with Cognitive Attenuations.Consensus statement update on posttraumatic stress disorder from the international consensus group on depression and anxiety.Lamotrigine for attention deficit-hyperactivity disorder comorbid with mood disorders: a case series.Perverse effects of the precautionary principle: how banning mephedrone has unexpected implications for pharmaceutical discovery.Benzodiazepines: risks and benefits. A reconsideration.Stimulants: use and abuse in the treatment of attention deficit hyperactivity disorder.The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology.The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans.
P50
Q21129387-085E27F2-752B-49D0-B59A-89B3D3ADDF43Q21203922-E00284AF-2071-4B2A-BA23-9C1702C313C6Q22241826-CBC4A12D-344C-4033-A788-12D762BCB52BQ24174843-3939c672-4747-0141-b386-fb2866e3e4faQ24296269-C080E804-06CA-4802-998B-54C1F2E713D7Q24602048-3D0E5650-32E2-464C-9CC6-E6AB2457670EQ24633222-F9025CD0-1D67-40AB-ADD2-CA3916A3348BQ28005551-B4DCFD69-05A1-4E69-895C-E795FF428A0FQ28079520-EB476383-2439-4E02-9C7B-98C8D90A6290Q28237791-F517AECE-B5CB-430D-8101-EAEC584E266EQ28242781-5E6C3B9C-4866-41F6-A1D2-873C1F35C667Q28260220-B7621705-9DD2-42CA-B43B-F9F53962DB48Q28269179-79E7AB21-C1CF-4B59-8712-E07482804738Q28274003-F404B18F-EF23-4D98-A972-679DE4A92DB8Q28292450-1BD841D9-9C00-437B-9BDA-63D2E79B4D21Q28294714-A702B905-600D-4F68-92B2-F384D1CEF2D3Q28304627-6C2C48F5-ADC2-4B8B-9665-20C43C717DB8Q28305435-2E19A7A4-CCC3-4E83-BE15-29C5ACFF27E1Q28534851-B564E517-E941-4F30-9137-704A4EAB2766Q30386974-960A0398-48FB-4CAF-92B3-A0394F278AA8Q30887773-6AC43402-06C7-47C4-80CF-B51C0085219AQ31099222-C64CB076-8E49-4BEA-BF95-019AFD09D716Q33652844-0A250891-C47E-4D9E-98C8-93735043DF75Q33729262-179F9C22-7A76-46D9-AF8E-F2EDA56A40DFQ34024516-13D02810-8B16-420D-A9CA-78867198B3E3Q34035251-F25076B0-7A58-47EF-9349-98B81C9DF6A5Q34064398-1963198A-8CD4-448B-B9E7-3CDB0AC6AE44Q34156657-5EED72C7-7496-4906-81D0-522595046728Q34192729-52BC85DB-5331-48BB-AE77-C2BC6F145D68Q34198014-649E22D0-1861-4364-B50E-C6524D4F5D43Q34258315-7A66B2BF-3D71-4257-A15F-1031E01988F0Q34259699-06B4EB49-0FC7-4E56-9C35-C6E19DBCB131Q34290395-CC180E5D-A5C3-41D0-BC60-D627FA8369EFQ34352157-F90FC9AB-6029-49DB-92CA-910E2E8FC912Q34367145-04DABB4C-F98F-4512-AA1C-9028B90E5562Q34373385-3D9B88DB-0FA4-45FC-8B63-6903CF205F84Q34386442-1F6CB153-C7A6-4D9D-A3B3-07393086E382Q34423309-1F9886B5-FC1D-4BC5-85E1-AA816EEAB777Q34465555-50832316-093F-4707-BE4A-777D2823D58DQ34465563-E38437F8-B2FF-430D-9659-69F5C9974A7E
P50
description
British psychiatrist, neuropsychopharmacologist
@en
Brits psychiater
@nl
Experte für Risiken von Drogen
@de
britisk psykiater
@da
psiquiatra británico
@es
Британский психиатр
@ru
name
David John Nutt
@an
David John Nutt
@da
David John Nutt
@eu
David John Nutt
@fo
David John Nutt
@gl
David John Nutt
@hu
David John Nutt
@is
David John Nutt
@it
David John Nutt
@kl
David John Nutt
@nn
type
label
David John Nutt
@an
David John Nutt
@da
David John Nutt
@eu
David John Nutt
@fo
David John Nutt
@gl
David John Nutt
@hu
David John Nutt
@is
David John Nutt
@it
David John Nutt
@kl
David John Nutt
@nn
altLabel
DJ Nutt
@da
DJ Nutt
@de
DJ Nutt
@en
David J Nutt
@da
David J Nutt
@de
David J Nutt
@en
David J Nutt
@fo
David J Nutt
@fr
David J Nutt
@is
David J Nutt
@kl
prefLabel
David John Nutt
@an
David John Nutt
@da
David John Nutt
@eu
David John Nutt
@fo
David John Nutt
@gl
David John Nutt
@hu
David John Nutt
@is
David John Nutt
@it
David John Nutt
@kl
David John Nutt
@nn